Clinical trial
Perioperative Esketamine Safety and Efficacy in Reducing Postoperative ENDometriosis PAIN (the ENDPAIN Trial): a Randomized Controlled Trial.
NCT07881562 is registered in ClinicalTrials.gov with Region Skane as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Perioperative Esketamine Safety and Efficacy in Reducing Postoperative ENDometriosis PAIN (the ENDPAIN Trial): a Randomized Controlled Trial.
- Lead sponsor
- Region Skane
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- January 1, 2028
- Completion date
- March 31, 2031
- Enrollment
- 1,000 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 2 arms.
-
Intervention group
They will receive esketamine as an adjunct to the standard postoperative pain therapy
-
Control group
They will receive placebo (NaCl)
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Time weighted longitudinal postoperative pain measurement over 48 hours.
A time-weighted longitudinal postoperative pain measurement over 48 hours, measured using the numeric rating scale (NRS, 0-10) for pain at 30 minutes after admission to the PACU, 6, 12, 24 and 48 hours postoperatively during activity (coughing or sitting)
Lead sponsor's other trials
Region Skane, most recent start first.
+379 more trials See the organization page
Similar trials
Same condition (Endometriosis) and phase, most recent start first.
+43 more trials See the condition page